Renal outcome after simultaneous heart and kidney transplantation.


Journal

Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240

Informations de publication

Date de publication:
07 2019
Historique:
received: 10 03 2019
revised: 10 05 2019
accepted: 20 05 2019
pubmed: 20 6 2019
medline: 9 9 2020
entrez: 20 6 2019
Statut: ppublish

Résumé

Simultaneous heart-kidney transplant (HKTx) is a valid treatment for patients with coexisting heart and renal failure. The aim of this study was to assess renal outcome in HKTx and to identify predictive factors for renal loss. A retrospective study was conducted among 73 HKTx recipients: Donors' and recipients' records were reviewed to evaluate patients' and renal transplants' survival and their prognostic factors. The mean follow-up was 5.36 years. Renal primary non-function occurred in 2.7%, and complications Clavien IIIb or higher were observed in 67.1% including 16 (22%) postoperative deaths. Five-year overall survival and renal survival were 74.5% and 69.4%. Among survivors, seven returned to dialysis during follow-up. The postoperative use of ECMO (HR = 6.04, P = 0.006), dialysis (HR = 1.04/day, P = 0.022), and occurrence of complications (HR = 31.79, P = 0.022) were independent predictors of postoperative mortality but not the history of previous HTx or KTx nor renal function prior to transplantation. History of KTx (HR = 2.52, P = 0.026) and increased delay between the two transplantations (HR = 1.25/hour, P = 0.018) were associated with renal transplant failure. HKTx provides good renal transplant survival and function, among survivors. Early mortality rate of 22% underlines the need to identify perioperative risk factors that would lead to more judicious and responsible allocation of a scarce resource.

Identifiants

pubmed: 31215696
doi: 10.1111/ctr.13615
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13615

Informations de copyright

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Théodore Toinet (T)

Department of Urology and Transplant Surgery, Hôpital Européen Georges-Pompidou, AP-HP, Université de Paris, Paris, France.

Inès Dominique (I)

Department of Urology and Transplant Surgery, Hôpital Edouard-Herriot, Hospices Civils de Lyon, Lyon, France.

Irène Cholley (I)

Department of Urology, AP-HP, Hôpital Henri Mondor, Créteil, France.

Victor Vanalderwerelt (V)

Department of Urology, CHRU de Tours, Tours, France.

Anna Goujon (A)

Department of Urology, CHU de Rennes, Rennes, France.

Fanny Paret (F)

Department of Urology, CHU de Nantes, Nantes, France.

Thomas Bessede (T)

Department of Urology, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Véronique Delaporte (V)

Department of Urology and Kidney Transplantation, AP-HM, CHU la Conception, Marseille, France.

Laurent Salomon (L)

Department of Urology, AP-HP, Hôpital Henri Mondor, Créteil, France.

Lionel Badet (L)

Department of Urology and Transplant Surgery, Hôpital Edouard-Herriot, Hospices Civils de Lyon, Lyon, France.

Jean-Michel Boutin (JM)

Department of Urology, CHRU de Tours, Tours, France.

Gregory Verhoest (G)

Department of Urology, CHU de Rennes, Rennes, France.

Julien Branchereau (J)

Department of Urology, CHU de Nantes, Nantes, France.

Marc-Olivier Timsit (MO)

Department of Urology and Transplant Surgery, Hôpital Européen Georges-Pompidou, AP-HP, Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH